Formycon/Fresenius Kabi and Samsung Bioepis Settlements with J&J and Janssen Biotech regarding Ustekinumab
LexBlog IP
AUGUST 16, 2023
The settlement permits marketing of FYB202 in the United States, subject to regulatory approval, no later than April 15, 2025. According to the press release, Formycon plans to submit a biologics license application later in 2023 to seek regulatory approval for FBY202. Economic terms of the settlement were not disclosed in the press release.
Let's personalize your content